Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need


KOL Webinar: Onvansertib for the Treatment of KRAS Mutated Metastatic Colorectal Cancer
 April 12, 2021
 8:00am - 9:30am PDT

The webinar will feature presentations by Key Opinion Leaders (KOLs) Daniel H. Ahn, D.O. (Mayo Clinic Arizona) and Manish R. Sharma, M.D. (START Midwest), who will discuss the current treatment landscape and unmet medical need in KRAS-mutated metastatic colorectal cancer (mCRC), as well as the ongoing Phase 1b/2 clinical trial and observations from the Expanded Access Program evaluating onvansertib in combination with FOLFIRI/Avastin® in KRAS-mutated mCRC.

During the webinar, Cardiff's CEO, Mark Erlander, Ph.D., will give a corporate update and outlook for the year. Dr. Erlander and Drs. Sharma and Ahn, will be available to answer questions following the conclusion of the formal presentations.